[1]段明明,欧阳君,刘贤升.雷珠单抗与康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的短期疗效比较[J].医学信息,2020,33(04):118-120.[doi:10.3969/j.issn.1006-1959.2020.04.036]
　DUAN Ming-ming,OUYANG Jun,LIU Xian-sheng.Comparison of Short-term Efficacy of Lucentis and Conbercept in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion[J].Medical Information,2020,33(04):118-120.[doi:10.3969/j.issn.1006-1959.2020.04.036]
点击复制

雷珠单抗与康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的短期疗效比较()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年04期
页码:
118-120
栏目:
临床研究
出版日期:
2020-02-15

文章信息/Info

Title:
Comparison of Short-term Efficacy of Lucentis and Conbercept in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion
文章编号:
1006-1959（2020）04-0118-03
作者:
段明明; 欧阳君; 刘贤升
（九江市第一人民医院眼科，江西 九江 332000）
Author(s):
DUAN Ming-ming; OUYANG Jun; LIU Xian-sheng
(Department of Ophthalmology,Jiujiang First People’s Hospital,Jiujiang 332000,Jiangxi,China)
关键词:
视网膜分支静脉阻塞; 黄斑水肿; 雷珠单抗; 康柏西普
Keywords:
Branch retinal vein occlusion; Macular edema; Lucentis; Conbercept
分类号:
R774.1
DOI:
10.3969/j.issn.1006-1959.2020.04.036
文献标志码:
A
摘要:
目的 比较雷珠单抗与康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的短期疗效。方法 选择2017年1月~2018年3月我院收治非缺血性视网膜分支静脉阻塞继发黄斑水肿患者46例（46眼），按随机数字表法分为A组和B组，每组23例。A组给予雷珠单抗注射，B组给予康柏西普组注射，比较两组术前、术后1、3个月最佳矫正视力（BCVA）、黄斑中心凹视网膜厚度（CMT）及并发症发生情况。结果 术后1、3个月，两组BCVA、CMT均高于术前，差异有统计学意义（P＜0.05）；两组BCVA、CMT比较，差异无统计学意义（P＞0.05）。两组并发症发生率比较，差异无统计学意义（P＞0.05）。结论 玻璃体腔注射雷珠单抗或康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿患者可有效提高BCVA、减少CMT，无明显全身或眼部重大不良反应，其疗效相当。
Abstract:
Objective To compare the short-term efficacy of Lucentis and Conbercept in the treatment of macular edema secondary to retinal vein occlusion.Methods From January 2017 to March 2018, 46 patients (46 eyes) with non-ischemic branch retinal vein occlusion secondary macular edema were treated in our hospital, and according to the random number table method,they were divided into group A and group B, 23 examples in each group. Group A was injected with Lucentis, and group B was injected with Conbercept and the best corrected visual acuity (BCVA), retinal thickness in macular fovea (CMT) and complications between the two groups 1 and 3 months after operation.Results At 1 and 3 months after operation, the BCVA and CMT in the two groups were higher than before surgery,the difference was statistically significant (P<0.05). There was no significant difference in BCVA and CMT between the two groups(P>0.05). There was no significant difference in the incidence of complications between the two groups(P>0.05).Conclusion Intravitreal injection of Lucentis or Conbercept in patients with secondary macular edema due to branch retinal vein occlusion can effectively increase BCVA and reduce CMT, without significant systemic or ocular major adverse effects, and its efficacy is comparable.

参考文献/References:

[1]Parodi MB,Bandello F.Branch retinal vein occlusion:classifica-tion and treatment[J].Ophthalmologica,2009,223(5):298-305. [2]Oellers P,Grewal DS,Fekrat S.Role of aflibercept for macular edema following branch retinal vein occlusion:comparison of clinical trials[J].Clin Ophthalmology,2016(10):411-418. [3]Zhang S,An N,Ha W,et al.Factors correlated with the resolution ofmacular oedema after one dose injection of intravitreal triamcinoloneacetonide treatment in branch retinal vein occlusion[J].Journal of International Medical Research,2016,44(3):685-697. [4]褚梦琪.视网膜静脉阻塞继发黄斑水肿的最新治疗进展[J].中华实验眼科杂志,2018,36(1):65-69. [5]邢凯,亢泽峰.玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的疗效分析[J].山东大学耳鼻喉眼学报,2016(1):80-82. [6]Wu Z,Zhou P,Li X,et al.Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling[J].PLoS One,2013,8(3):e57642. [7]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471-473. [8]杨林红,皇甫昌涛,朱琳,等.眼内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的临床观察[J].昆明医科大学学报,2015,36(11):147-149. [9]连海燕,宋艳萍,丁琴,等.康柏西普与雷珠单抗玻璃体腔注射治疗视网膜中央静脉阻塞黄斑水肿短期疗效对比观察[J].中华眼底病杂志,2016,32(4):367-371.

相似文献/References:

[1]司 昕,高 磊,高荣玉,等.视网膜静脉阻塞后视网膜缺血的研究现状[J].医学信息,2021,34(15):25.[doi:10.3969/j.issn.1006-1959.2021.15.007]
　SI Xin,GAO Lei,GAO Rong-yu,et al.Current Research Status of Retinal Ischemia After Retinal Vein Occlusion[J].Medical Information,2021,34(04):25.[doi:10.3969/j.issn.1006-1959.2021.15.007]

更新日期/Last Update: 2020-02-15